Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
When vision fades: Rethinking wet AMD and the durability gap
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
The supply chain fault lines of modern pharma
Breaking borders: Building biotech scale in Benelux
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.